THE IN VITRO ANTIOXIDANT PROPERTIES OF 2-ALKOXYPHENYLCARBAMIC ACID DERIVATIVES CONTAINING A 4 '-(SUBSTITUTED PHENYL) PIPERAZIN- 1 '- YL MOIETY DETERMINED BY THE 2,2 '- AZINOBIS(3-ETHYLBENZOTHIAZOLINE-6-SULFONIC ACID) DERIVED RADICAL CATION (ABTS(center dot+)) AND FERRIC REDUCING ANTIOXIDANT POWER (FRAP) ASSAYS
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F17%3A43876152" target="_blank" >RIV/62157124:16370/17:43876152 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.14499/indonesianjpharm28iss1pp1" target="_blank" >http://dx.doi.org/10.14499/indonesianjpharm28iss1pp1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14499/indonesianjpharm28iss1pp1" target="_blank" >10.14499/indonesianjpharm28iss1pp1</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
THE IN VITRO ANTIOXIDANT PROPERTIES OF 2-ALKOXYPHENYLCARBAMIC ACID DERIVATIVES CONTAINING A 4 '-(SUBSTITUTED PHENYL) PIPERAZIN- 1 '- YL MOIETY DETERMINED BY THE 2,2 '- AZINOBIS(3-ETHYLBENZOTHIAZOLINE-6-SULFONIC ACID) DERIVED RADICAL CATION (ABTS(center dot+)) AND FERRIC REDUCING ANTIOXIDANT POWER (FRAP) ASSAYS
Popis výsledku v původním jazyce
In an effort to comprehensively characterize an antioxidant profile of 2-alkoxyphenylcarbamic acid-based compounds containing a 4 '-(substituted phenyl) piperazin-1 '- yl fragment, they were in vitro screened in the 2,2 ' -azino-bis(3-ethylbenzothiazoline-6- sulfonic acid) derived radical cation (ABTS(center dot+)) and ferric reducing antioxidant power (FRAP) assay using the UV/VIS spectrophotometry. The ABTS(center dot+) scavenging (reducing) potential of 1-[3-(2-methoxyphenylcarbamoyl) oxy-2- hydroxypropyl]-4-(4-fluorophenyl) piperazin-1-ium chloride was found to be the most promising and it was comparable to the efficiency of the carvedilol reference drug. Moreover, that 4 ' - fluoro group-containing compound was regarded as more active than the atenolol standard. When testing the molecules ' power to reduce the ferric 2,4,6-tris (2-pyridyl)-s-triazine complex [Fe(III)(TPTZ) 2] (3+), the most prospective was 1-[3-(2-ethoxyphenylcarbamoyl) oxy-2- hydroxypropyl]- 4-( 4-fluorophenyl) piperazin-1-ium chloride. On the other hand, its Fe3+ reducing power was lower compared to both standards carvedilol and atenolol. The study discussed structure-antioxidant properties relationships considering electronic, steric and lipophilic features.
Název v anglickém jazyce
THE IN VITRO ANTIOXIDANT PROPERTIES OF 2-ALKOXYPHENYLCARBAMIC ACID DERIVATIVES CONTAINING A 4 '-(SUBSTITUTED PHENYL) PIPERAZIN- 1 '- YL MOIETY DETERMINED BY THE 2,2 '- AZINOBIS(3-ETHYLBENZOTHIAZOLINE-6-SULFONIC ACID) DERIVED RADICAL CATION (ABTS(center dot+)) AND FERRIC REDUCING ANTIOXIDANT POWER (FRAP) ASSAYS
Popis výsledku anglicky
In an effort to comprehensively characterize an antioxidant profile of 2-alkoxyphenylcarbamic acid-based compounds containing a 4 '-(substituted phenyl) piperazin-1 '- yl fragment, they were in vitro screened in the 2,2 ' -azino-bis(3-ethylbenzothiazoline-6- sulfonic acid) derived radical cation (ABTS(center dot+)) and ferric reducing antioxidant power (FRAP) assay using the UV/VIS spectrophotometry. The ABTS(center dot+) scavenging (reducing) potential of 1-[3-(2-methoxyphenylcarbamoyl) oxy-2- hydroxypropyl]-4-(4-fluorophenyl) piperazin-1-ium chloride was found to be the most promising and it was comparable to the efficiency of the carvedilol reference drug. Moreover, that 4 ' - fluoro group-containing compound was regarded as more active than the atenolol standard. When testing the molecules ' power to reduce the ferric 2,4,6-tris (2-pyridyl)-s-triazine complex [Fe(III)(TPTZ) 2] (3+), the most prospective was 1-[3-(2-ethoxyphenylcarbamoyl) oxy-2- hydroxypropyl]- 4-( 4-fluorophenyl) piperazin-1-ium chloride. On the other hand, its Fe3+ reducing power was lower compared to both standards carvedilol and atenolol. The study discussed structure-antioxidant properties relationships considering electronic, steric and lipophilic features.
Klasifikace
Druh
J<sub>ost</sub> - Ostatní články v recenzovaných periodicích
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Indonesian journal of pharmacy
ISSN
2338-9427
e-ISSN
—
Svazek periodika
28
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
ID - Indonéská republika
Počet stran výsledku
9
Strana od-do
1-9
Kód UT WoS článku
000411629700001
EID výsledku v databázi Scopus
—